Skip to main content

Table 2 Type-specific high-risk HPV prevalence and incidence among HIV-negative high-risk women with normal cytology, Kigali, Rwanda

From: The epidemiology of human papillomavirus infection in HIV-positive and HIV-negative high-risk women in Kigali, Rwanda

 

Prevalence*

Incidence†

 

No at risk

No cases

Prevalence proportion % (95% CI)

No at risk

No cases

Incidence proportion % (95% CI)

Any HR

349

105

31 (26-36)

296

82

28 (23-33)

Alpha 9 (HPV-16-related types)

16

349

19

5 (3-8)

282

12

4 (2-7)

31

349

11

3 (1-5)

286

10

3 (1-6)

33

349

7

2 (1-4)

289

8

3 (1-5)

35

349

12

4 (2-6)

285

4

1 (0-3)

52

349

15

4 (2-6)

287

16

6 (3-8)

58

349

14

4 (2-6)

284

10

4 (1-6)

Alpha 7 (HPV-18 related types)

18

349

11

3 (1-5)

289

13

4 (2-7)

39

349

8

2 (1-4)

290

5

2 (0-3)

45

349

17

5 (3-7)

281

7

2 (1-4)

59

349

11

3 (1-5)

286

12

4 (2-7)

68

349

13

4 (2-6)

286

7

2 (1-4)

Other types

51

349

12

4 (2-6)

287

11

4 (2-6)

56

349

8

2 (1-4)

290

8

3 (1-5)

73

349

5

1 (0-3)

291

3

1 (0-2)

82

349

1

0 (0-1)

295

3

1 (0-2)

Iso39

349

1

0 (0-1)

295

1

0 (0-1)

  1. *Type-specific prevalence at M6 visit. Population at risk includes HIV-negative women with/without HR-HPV co-infection with other types than the type at interest; †Type-specific incidence. Population at risk includes HIV-negative women with/without HR-HPV infection with other types than the type at interest.; 320 women had HPV results at M6 and Year 2; 15 were excluded because of abnormal cytology results; another 9 because HIV seroconversion; mean interval incidence 16.6 months (SD 1.8)
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us